Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 174 | 2024 | 3143 | 14.200 |
Why?
|
Kidney Neoplasms | 162 | 2024 | 4262 | 12.350 |
Why?
|
Interleukin-2 | 35 | 2019 | 1904 | 4.210 |
Why?
|
Melanoma | 62 | 2024 | 5510 | 3.760 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 78 | 2023 | 11524 | 3.740 |
Why?
|
Immunotherapy | 43 | 2023 | 4445 | 3.220 |
Why?
|
Antibodies, Monoclonal | 50 | 2022 | 9274 | 2.840 |
Why?
|
Antineoplastic Agents | 67 | 2024 | 13695 | 2.160 |
Why?
|
Vascular Endothelial Growth Factor A | 30 | 2024 | 3508 | 1.700 |
Why?
|
Interferon-alpha | 13 | 2018 | 895 | 1.420 |
Why?
|
Phenylurea Compounds | 19 | 2024 | 528 | 1.410 |
Why?
|
Angiogenesis Inhibitors | 23 | 2022 | 2038 | 1.160 |
Why?
|
Molecular Targeted Therapy | 19 | 2019 | 2727 | 1.160 |
Why?
|
Neoplasm Metastasis | 40 | 2019 | 4851 | 0.940 |
Why?
|
Skin Neoplasms | 26 | 2022 | 5686 | 0.920 |
Why?
|
Niacinamide | 13 | 2022 | 417 | 0.890 |
Why?
|
Indoles | 19 | 2019 | 1839 | 0.880 |
Why?
|
Pyrroles | 16 | 2018 | 1146 | 0.830 |
Why?
|
Quinolines | 6 | 2024 | 732 | 0.680 |
Why?
|
Treatment Outcome | 76 | 2021 | 63114 | 0.670 |
Why?
|
Humans | 243 | 2024 | 744343 | 0.660 |
Why?
|
Survival Rate | 24 | 2021 | 12788 | 0.640 |
Why?
|
Protein Kinase Inhibitors | 20 | 2024 | 5535 | 0.610 |
Why?
|
Disease-Free Survival | 28 | 2022 | 6895 | 0.610 |
Why?
|
Clinical Trials as Topic | 16 | 2019 | 7913 | 0.600 |
Why?
|
Neoplasm Staging | 30 | 2020 | 11031 | 0.600 |
Why?
|
Prognosis | 38 | 2023 | 29063 | 0.600 |
Why?
|
Cytokines | 11 | 2023 | 7322 | 0.580 |
Why?
|
Middle Aged | 125 | 2023 | 213383 | 0.560 |
Why?
|
Aged | 101 | 2022 | 163280 | 0.530 |
Why?
|
Survival Analysis | 26 | 2022 | 10252 | 0.510 |
Why?
|
Sirolimus | 10 | 2018 | 1564 | 0.500 |
Why?
|
Cancer Vaccines | 5 | 2013 | 1023 | 0.500 |
Why?
|
Male | 144 | 2023 | 350118 | 0.500 |
Why?
|
Proto-Oncogene Proteins B-raf | 11 | 2019 | 2043 | 0.490 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 7 | 2024 | 664 | 0.480 |
Why?
|
Kaplan-Meier Estimate | 23 | 2019 | 6538 | 0.480 |
Why?
|
gp100 Melanoma Antigen | 1 | 2013 | 39 | 0.470 |
Why?
|
Female | 140 | 2023 | 380194 | 0.460 |
Why?
|
Maximum Tolerated Dose | 8 | 2017 | 892 | 0.460 |
Why?
|
Antigens, Neoplasm | 5 | 2020 | 1988 | 0.440 |
Why?
|
Aged, 80 and over | 48 | 2021 | 57776 | 0.440 |
Why?
|
Sulfonamides | 6 | 2021 | 1938 | 0.440 |
Why?
|
Dose-Response Relationship, Drug | 18 | 2021 | 10943 | 0.440 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 9 | 2021 | 1038 | 0.430 |
Why?
|
Benzenesulfonates | 8 | 2011 | 169 | 0.420 |
Why?
|
Adult | 87 | 2022 | 214055 | 0.410 |
Why?
|
Urogenital Neoplasms | 1 | 2013 | 137 | 0.410 |
Why?
|
Angiopoietin-2 | 3 | 2021 | 173 | 0.390 |
Why?
|
Endogenous Retroviruses | 2 | 2023 | 112 | 0.390 |
Why?
|
Follow-Up Studies | 21 | 2023 | 39050 | 0.380 |
Why?
|
Neovascularization, Pathologic | 8 | 2020 | 2635 | 0.380 |
Why?
|
CD8-Positive T-Lymphocytes | 7 | 2023 | 4479 | 0.380 |
Why?
|
Neoplasms | 14 | 2023 | 21683 | 0.360 |
Why?
|
Indazoles | 4 | 2021 | 289 | 0.340 |
Why?
|
Nephrectomy | 7 | 2021 | 1050 | 0.330 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2017 | 629 | 0.330 |
Why?
|
Receptors, KIR | 2 | 2020 | 113 | 0.330 |
Why?
|
Imidazoles | 4 | 2019 | 1206 | 0.290 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2022 | 8428 | 0.270 |
Why?
|
Recombinant Proteins | 10 | 2018 | 6622 | 0.270 |
Why?
|
Pyridines | 10 | 2017 | 2825 | 0.270 |
Why?
|
Salvage Therapy | 3 | 2023 | 1275 | 0.270 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2024 | 841 | 0.270 |
Why?
|
Pyrimidines | 4 | 2021 | 2942 | 0.260 |
Why?
|
Drug Administration Schedule | 13 | 2018 | 4933 | 0.260 |
Why?
|
Retreatment | 4 | 2020 | 610 | 0.250 |
Why?
|
Skin Diseases | 1 | 2013 | 1065 | 0.250 |
Why?
|
Research Design | 5 | 2019 | 5987 | 0.250 |
Why?
|
Drug Therapy, Combination | 8 | 2020 | 6489 | 0.250 |
Why?
|
TOR Serine-Threonine Kinases | 10 | 2020 | 2109 | 0.240 |
Why?
|
Quality of Life | 8 | 2023 | 12804 | 0.240 |
Why?
|
Antibodies, Neoplasm | 2 | 2016 | 286 | 0.230 |
Why?
|
Immunomodulation | 2 | 2018 | 541 | 0.230 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 783 | 0.230 |
Why?
|
Mutation | 17 | 2021 | 29786 | 0.230 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2014 | 903 | 0.230 |
Why?
|
T-Lymphocytes | 9 | 2020 | 10180 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9239 | 0.210 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 9959 | 0.210 |
Why?
|
Adjuvants, Immunologic | 3 | 2023 | 1000 | 0.210 |
Why?
|
Butylamines | 1 | 2021 | 8 | 0.200 |
Why?
|
Immunohistochemistry | 12 | 2019 | 11366 | 0.200 |
Why?
|
Immunoglobulins | 2 | 2023 | 881 | 0.190 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 315 | 0.190 |
Why?
|
Quinazolines | 1 | 2007 | 1356 | 0.190 |
Why?
|
Disease Progression | 9 | 2022 | 13284 | 0.190 |
Why?
|
Aminoquinolines | 1 | 2021 | 109 | 0.190 |
Why?
|
Double-Blind Method | 8 | 2022 | 12026 | 0.190 |
Why?
|
Deoxycytidine | 3 | 2015 | 826 | 0.190 |
Why?
|
Models, Economic | 3 | 2020 | 713 | 0.180 |
Why?
|
International Agencies | 1 | 2021 | 240 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 252 | 0.180 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2219 | 0.180 |
Why?
|
Tumor Microenvironment | 6 | 2023 | 3586 | 0.180 |
Why?
|
Sarcoma | 2 | 2023 | 1897 | 0.180 |
Why?
|
5'-Nucleotidase | 1 | 2020 | 160 | 0.170 |
Why?
|
Carbonic Anhydrases | 3 | 2010 | 115 | 0.170 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2023 | 1114 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 212 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2012 | 578 | 0.160 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5221 | 0.160 |
Why?
|
Combined Modality Therapy | 6 | 2022 | 8642 | 0.160 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 109 | 0.160 |
Why?
|
Azetidines | 1 | 2019 | 142 | 0.150 |
Why?
|
Infusions, Intravenous | 6 | 2017 | 2274 | 0.150 |
Why?
|
Oximes | 1 | 2019 | 311 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2020 | 5172 | 0.150 |
Why?
|
Interleukin-8 | 1 | 2020 | 690 | 0.150 |
Why?
|
4-1BB Ligand | 1 | 2016 | 29 | 0.150 |
Why?
|
Viral Envelope Proteins | 1 | 2020 | 635 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2019 | 371 | 0.140 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 253 | 0.140 |
Why?
|
Galectin 1 | 1 | 2017 | 131 | 0.140 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 310 | 0.140 |
Why?
|
Drug Synergism | 2 | 2019 | 1792 | 0.140 |
Why?
|
Receptors, CXCR4 | 1 | 2021 | 726 | 0.140 |
Why?
|
Young Adult | 15 | 2021 | 56430 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 434 | 0.130 |
Why?
|
Heart Diseases | 1 | 2009 | 2788 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3479 | 0.130 |
Why?
|
Benzimidazoles | 1 | 2021 | 850 | 0.130 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2016 | 370 | 0.130 |
Why?
|
Computer Simulation | 2 | 2020 | 6196 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2022 | 2245 | 0.130 |
Why?
|
Clinical Protocols | 2 | 2019 | 1462 | 0.130 |
Why?
|
Autoimmune Diseases | 3 | 2019 | 2133 | 0.120 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 9438 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 546 | 0.120 |
Why?
|
Pyridones | 1 | 2019 | 712 | 0.120 |
Why?
|
Paclitaxel | 3 | 2011 | 1708 | 0.120 |
Why?
|
Endpoint Determination | 1 | 2017 | 601 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
Anilides | 2 | 2016 | 408 | 0.120 |
Why?
|
Models, Organizational | 1 | 2017 | 574 | 0.110 |
Why?
|
Soft Tissue Neoplasms | 1 | 2023 | 1363 | 0.110 |
Why?
|
Retrospective Studies | 24 | 2021 | 77449 | 0.110 |
Why?
|
Receptors, IgG | 1 | 2016 | 582 | 0.110 |
Why?
|
Survival | 1 | 2013 | 163 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 3 | 2021 | 2849 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 911 | 0.110 |
Why?
|
Costs and Cost Analysis | 1 | 2018 | 1681 | 0.110 |
Why?
|
Interleukin-6 | 1 | 2023 | 3200 | 0.110 |
Why?
|
Lung Neoplasms | 4 | 2024 | 13102 | 0.110 |
Why?
|
Dacarbazine | 2 | 2008 | 566 | 0.110 |
Why?
|
Death | 1 | 2017 | 678 | 0.110 |
Why?
|
Chemokine CXCL10 | 3 | 2019 | 304 | 0.100 |
Why?
|
Cardiac Tamponade | 1 | 2013 | 173 | 0.100 |
Why?
|
Palliative Care | 2 | 2017 | 3493 | 0.100 |
Why?
|
Tumor Burden | 3 | 2015 | 1915 | 0.100 |
Why?
|
Patient Selection | 3 | 2009 | 4215 | 0.100 |
Why?
|
Kidney | 3 | 2017 | 7186 | 0.100 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2019 | 1821 | 0.100 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2021 | 290 | 0.100 |
Why?
|
Databases, Factual | 3 | 2023 | 7729 | 0.100 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 627 | 0.100 |
Why?
|
Fatigue | 4 | 2022 | 1531 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1142 | 0.100 |
Why?
|
Perioperative Care | 1 | 2019 | 1002 | 0.100 |
Why?
|
Gene Expression | 2 | 2022 | 7799 | 0.100 |
Why?
|
Medical Oncology | 3 | 2020 | 2265 | 0.100 |
Why?
|
Immunologic Factors | 2 | 2020 | 1580 | 0.100 |
Why?
|
Metabolomics | 1 | 2019 | 1484 | 0.100 |
Why?
|
Time Factors | 9 | 2021 | 40075 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2019 | 2728 | 0.090 |
Why?
|
Hyponatremia | 1 | 2013 | 298 | 0.090 |
Why?
|
Piperidines | 1 | 2019 | 1602 | 0.090 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2010 | 772 | 0.090 |
Why?
|
Prospective Studies | 11 | 2022 | 53288 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3772 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2018 | 4803 | 0.090 |
Why?
|
Carboplatin | 2 | 2011 | 801 | 0.090 |
Why?
|
Myeloid Cells | 2 | 2023 | 810 | 0.090 |
Why?
|
Neoplasm Proteins | 2 | 2013 | 3703 | 0.080 |
Why?
|
Chromosomes, Human, X | 1 | 2010 | 296 | 0.080 |
Why?
|
Brain Neoplasms | 3 | 2022 | 8863 | 0.080 |
Why?
|
Amylases | 2 | 2019 | 173 | 0.080 |
Why?
|
Sodium | 1 | 2013 | 1623 | 0.080 |
Why?
|
Cardiovascular System | 1 | 2015 | 832 | 0.080 |
Why?
|
Lymphocyte Depletion | 1 | 2010 | 608 | 0.080 |
Why?
|
DNA Mutational Analysis | 2 | 2014 | 4186 | 0.080 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2021 | 449 | 0.080 |
Why?
|
Genetic Association Studies | 2 | 2016 | 2703 | 0.070 |
Why?
|
Signal Transduction | 7 | 2021 | 23403 | 0.070 |
Why?
|
Lipase | 2 | 2019 | 314 | 0.070 |
Why?
|
Injections, Subcutaneous | 2 | 2005 | 666 | 0.070 |
Why?
|
Biomedical Research | 1 | 2022 | 3309 | 0.070 |
Why?
|
Ligands | 3 | 2022 | 3282 | 0.070 |
Why?
|
Alanine Transaminase | 2 | 2019 | 592 | 0.070 |
Why?
|
Protein Kinases | 3 | 2007 | 1640 | 0.070 |
Why?
|
Patient Care Team | 1 | 2017 | 2531 | 0.070 |
Why?
|
Karnofsky Performance Status | 2 | 2017 | 173 | 0.070 |
Why?
|
Proportional Hazards Models | 6 | 2017 | 12354 | 0.070 |
Why?
|
Cohort Studies | 7 | 2017 | 40561 | 0.060 |
Why?
|
Arginase | 1 | 2005 | 79 | 0.060 |
Why?
|
Translocation, Genetic | 1 | 2010 | 1420 | 0.060 |
Why?
|
Interferon-gamma | 4 | 2020 | 3206 | 0.060 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2016 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2013 | 2258 | 0.060 |
Why?
|
Animals | 7 | 2023 | 168757 | 0.060 |
Why?
|
Cell Movement | 1 | 2016 | 5217 | 0.060 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2008 | 627 | 0.060 |
Why?
|
Survivors | 1 | 2014 | 2291 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5853 | 0.060 |
Why?
|
Capillary Permeability | 1 | 2007 | 798 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 3 | 2015 | 776 | 0.060 |
Why?
|
Placebos | 1 | 2007 | 1676 | 0.050 |
Why?
|
United States | 9 | 2022 | 69872 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2020 | 2012 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Transcription Factors | 2 | 2020 | 12208 | 0.050 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 5391 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Ambulatory Care Facilities | 2 | 2017 | 933 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 2 | 2020 | 2505 | 0.050 |
Why?
|
Genotype | 4 | 2016 | 12951 | 0.050 |
Why?
|
Administration, Oral | 1 | 2008 | 3913 | 0.050 |
Why?
|
Antineoplastic Protocols | 1 | 2020 | 50 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2618 | 0.040 |
Why?
|
Outpatients | 1 | 2007 | 1486 | 0.040 |
Why?
|
Pyrazoles | 1 | 2010 | 1972 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4026 | 0.040 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 234 | 0.040 |
Why?
|
Antigen Presentation | 2 | 2020 | 1284 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 434 | 0.040 |
Why?
|
Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
Spin Labels | 1 | 2020 | 332 | 0.040 |
Why?
|
Granzymes | 1 | 2020 | 271 | 0.040 |
Why?
|
Kynurenine | 1 | 2019 | 139 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.040 |
Why?
|
Dendritic Cells | 2 | 2007 | 2725 | 0.040 |
Why?
|
Predictive Value of Tests | 4 | 2011 | 15076 | 0.040 |
Why?
|
Immunotherapy, Adoptive | 1 | 2007 | 1270 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.040 |
Why?
|
Tyrosine | 1 | 2023 | 1461 | 0.040 |
Why?
|
Adolescent | 5 | 2019 | 85781 | 0.040 |
Why?
|
Paresthesia | 1 | 2019 | 161 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2019 | 426 | 0.040 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 2538 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2018 | 1182 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 705 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 114 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2020 | 35421 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2020 | 321 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 478 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15519 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6234 | 0.040 |
Why?
|
Risk Factors | 4 | 2022 | 72290 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2021 | 3597 | 0.040 |
Why?
|
Up-Regulation | 2 | 2016 | 4217 | 0.040 |
Why?
|
Erythropoietin | 1 | 2021 | 726 | 0.040 |
Why?
|
Chemokine CXCL9 | 1 | 2016 | 132 | 0.030 |
Why?
|
Pruritus | 1 | 2019 | 361 | 0.030 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.030 |
Why?
|
Urologic Neoplasms | 1 | 2020 | 318 | 0.030 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 890 | 0.030 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 670 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2015 | 68 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 742 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.030 |
Why?
|
Piperazines | 1 | 2006 | 2488 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2020 | 1401 | 0.030 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2017 | 261 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 987 | 0.030 |
Why?
|
Urology | 1 | 2020 | 399 | 0.030 |
Why?
|
Registries | 2 | 2023 | 8089 | 0.030 |
Why?
|
raf Kinases | 1 | 2015 | 122 | 0.030 |
Why?
|
Genomics | 2 | 2022 | 5720 | 0.030 |
Why?
|
Proteinuria | 1 | 2018 | 658 | 0.030 |
Why?
|
Genetic Heterogeneity | 1 | 2018 | 733 | 0.030 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2024 | 2988 | 0.030 |
Why?
|
Chemokine CX3CL1 | 1 | 2014 | 58 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13881 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1660 | 0.030 |
Why?
|
Macrophages | 2 | 2021 | 5655 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2020 | 16689 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1423 | 0.030 |
Why?
|
Health Plan Implementation | 1 | 2017 | 352 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 707 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1338 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 6314 | 0.030 |
Why?
|
Decision Trees | 1 | 2015 | 506 | 0.030 |
Why?
|
Finland | 1 | 2014 | 602 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.030 |
Why?
|
Glomerular Filtration Rate | 2 | 2011 | 2170 | 0.030 |
Why?
|
Prostatic Neoplasms | 2 | 2013 | 11124 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 808 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2017 | 599 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20129 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 571 | 0.030 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 1312 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1641 | 0.030 |
Why?
|
Codon | 1 | 2014 | 611 | 0.030 |
Why?
|
Italy | 1 | 2014 | 832 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2017 | 598 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2016 | 1155 | 0.030 |
Why?
|
Aminopyridines | 1 | 2016 | 542 | 0.030 |
Why?
|
Gene Deletion | 1 | 2020 | 2751 | 0.030 |
Why?
|
Asia | 1 | 2013 | 610 | 0.030 |
Why?
|
Chemokines | 1 | 2016 | 970 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2020 | 9648 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2015 | 673 | 0.030 |
Why?
|
Fever | 1 | 2019 | 1616 | 0.030 |
Why?
|
Killer Cells, Natural | 1 | 2020 | 2133 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6386 | 0.020 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7279 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 2886 | 0.020 |
Why?
|
Adaptive Immunity | 1 | 2016 | 713 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2017 | 2971 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2455 | 0.020 |
Why?
|
Lymphopenia | 1 | 2013 | 285 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81183 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2017 | 956 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 648 | 0.020 |
Why?
|
Odds Ratio | 2 | 2019 | 9849 | 0.020 |
Why?
|
Risk | 2 | 2018 | 9687 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1758 | 0.020 |
Why?
|
Myocarditis | 1 | 2018 | 771 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2015 | 719 | 0.020 |
Why?
|
Hospice Care | 1 | 2017 | 672 | 0.020 |
Why?
|
Compassionate Use Trials | 1 | 2010 | 46 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2014 | 1791 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2016 | 3144 | 0.020 |
Why?
|
Pilot Projects | 3 | 2010 | 8324 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3616 | 0.020 |
Why?
|
Canada | 1 | 2014 | 2065 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2959 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2017 | 941 | 0.020 |
Why?
|
Hypertension | 2 | 2019 | 8480 | 0.020 |
Why?
|
Computational Biology | 1 | 2020 | 3521 | 0.020 |
Why?
|
Phenotype | 2 | 2016 | 16365 | 0.020 |
Why?
|
Lymphocytes | 1 | 2016 | 2617 | 0.020 |
Why?
|
Models, Biological | 2 | 2019 | 9583 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1836 | 0.020 |
Why?
|
Hypotension | 1 | 2013 | 884 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2005 | 5181 | 0.020 |
Why?
|
Europe | 1 | 2013 | 3339 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7722 | 0.020 |
Why?
|
North America | 1 | 2010 | 1249 | 0.020 |
Why?
|
Digestive System Diseases | 1 | 2007 | 147 | 0.020 |
Why?
|
Skin | 1 | 2019 | 4364 | 0.020 |
Why?
|
Safety | 1 | 2010 | 1186 | 0.020 |
Why?
|
Ornithine | 1 | 2005 | 78 | 0.020 |
Why?
|
Cell Membrane | 1 | 2015 | 3748 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2006 | 188 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3647 | 0.020 |
Why?
|
Terminal Care | 1 | 2017 | 1694 | 0.020 |
Why?
|
Health Care Costs | 1 | 2018 | 3209 | 0.020 |
Why?
|
Risk Assessment | 2 | 2017 | 23338 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2016 | 4420 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1364 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2012 | 1788 | 0.020 |
Why?
|
Observer Variation | 1 | 2011 | 2593 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2014 | 19905 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2016 | 2958 | 0.020 |
Why?
|
Body Mass Index | 1 | 2022 | 12720 | 0.020 |
Why?
|
Hybrid Cells | 1 | 2004 | 441 | 0.020 |
Why?
|
Doxorubicin | 1 | 2011 | 2234 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2007 | 1799 | 0.010 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 379 | 0.010 |
Why?
|
Massachusetts | 1 | 2017 | 8663 | 0.010 |
Why?
|
Medical Records | 1 | 2009 | 1413 | 0.010 |
Why?
|
Electrons | 1 | 2005 | 268 | 0.010 |
Why?
|
Incidence | 1 | 2022 | 20947 | 0.010 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2005 | 221 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13989 | 0.010 |
Why?
|
Vaccination | 2 | 2007 | 3278 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 2559 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2008 | 1850 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2007 | 498 | 0.010 |
Why?
|
Area Under Curve | 1 | 2007 | 1654 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3527 | 0.010 |
Why?
|
Drug Costs | 1 | 2010 | 1105 | 0.010 |
Why?
|
Exanthema | 1 | 2007 | 501 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2008 | 740 | 0.010 |
Why?
|
Respiratory Tract Diseases | 1 | 2007 | 722 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15540 | 0.010 |
Why?
|
Alleles | 1 | 2012 | 6933 | 0.010 |
Why?
|
Renal Dialysis | 1 | 2011 | 1786 | 0.010 |
Why?
|
Societies, Medical | 1 | 2013 | 3743 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3610 | 0.010 |
Why?
|
Arginine | 1 | 2005 | 944 | 0.010 |
Why?
|
Vinblastine | 1 | 2002 | 502 | 0.010 |
Why?
|
Interleukin-12 | 1 | 2003 | 579 | 0.010 |
Why?
|
Cytoplasm | 1 | 2005 | 1539 | 0.010 |
Why?
|
Benzamides | 1 | 2006 | 1379 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2004 | 1341 | 0.010 |
Why?
|
Medicare | 1 | 2018 | 6566 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2011 | 2759 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Forecasting | 1 | 2009 | 2951 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18370 | 0.010 |
Why?
|
Obesity | 1 | 2022 | 12745 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 3870 | 0.010 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2002 | 648 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14722 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 884 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2007 | 2503 | 0.010 |
Why?
|
Cell Separation | 1 | 2004 | 1751 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8340 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9313 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2004 | 20822 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18029 | 0.010 |
Why?
|
Cisplatin | 1 | 2002 | 1662 | 0.010 |
Why?
|
Phosphorylation | 1 | 2007 | 8436 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2007 | 1912 | 0.010 |
Why?
|
Acute Kidney Injury | 1 | 2007 | 1972 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2007 | 3479 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2005 | 5524 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2004 | 5974 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17446 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12959 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6773 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2007 | 19229 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2004 | 10481 | 0.010 |
Why?
|